The LEADERs Program at Northeastern University’s Post

Ryan Murray, PhD’24, cut his own path to developing an emerging gene-edited cell therapy that could one day personalize treatment for disease. After completing his Industry PhD in Stephen Hatfield's lab, he co-founded KiraGen Bio. “I never thought I’d be an entrepreneur. I wanted to be in early science discovery, but through the LEADERs program I learned there’s other things you can do with your PhD that are still very scientifically focused in early-stage research,” says Murray, who worked at Northeastern University Center for Research Innovation (CRI). “You don’t have to be the one sitting there pipetting.” Click to read the full article. https://lnkd.in/eZRFFSEK Murray started KiraGen Bio with Aaron Edwards, who recently earned a dual degree from Harvard Business School and Harvard Kenneth C. Griffin Graduate School of Arts and Sciences. Northeastern University. The LEADERs Program at Northeastern University. Fifty Years. #biotech #startup #entrepreneurship #industryphd #phdeducation #geneediting Northeastern University School of Pharmacy and Pharmaceutical Sciences.

A primer on how docking and virtual screening are used in drug discovery. Once you have a biological target and an idea of how you want to modify that target, the next step is often to find a molecule that hits that target as a starting point for a drug. Docking and virtual screening allow you to model the interaction between molecules and targets computationally, filtering billions of options to an amount testable in lab. Though be warned, the ability of docking and virtual screening to separate true hits from false positives remains limited... https://lnkd.in/dGTX9XU2 #drugDiscovery #molecularBiology #chemistry #computationalChemistry #startups #entrepreneurship

Latest DON Therapeutics news. Biotech startups are at the forefront of medical innovation, driving breakthroughs in areas like gene therapy, personalised medicine, and digital health. However, these startups face significant funding challenges due to the high costs associated with research, development, and regulatory approvals. Securing robust funding is crucial for transforming groundbreaking ideas into viable treatments and technologies. Early-stage investments and venture capital are vital in helping these startups navigate the complex journey from concept to market. Investors play a pivotal role in this ecosystem, providing the necessary capital and strategic guidance to advance these ventures. By supporting biotech startups, investors not only contribute to the growth of a dynamic industry but also to the development of innovative solutions that can improve global health outcomes. As we continue to witness rapid advancements in biotechnology, it is essential to ensure that these startups have the financial resources needed to succeed. Supporting biotech startups is essential for fostering a healthier, more innovative future. More about DON Therapeutics: https://lnkd.in/eKs-9g9e We are always looking for new healthcare opportunities. Submit your opportunity: https://lnkd.in/dJfhwVvv #biotech #investments #medical #innovation #research #funding #opportunities #strategicpartnerships #seriesa #seriesb #europe #usa

𝗧𝗵𝗲 𝗙𝗼𝘂𝗻𝗱𝗲𝗿 𝗙𝗶𝗹𝗲𝘀 by CRIMSON Founders introduces, SyzOnc, founded by  + Massachusetts Institute of Technology and Harvard University alumna Anne Carpenter, PhD | Scientific Advisor + University of Pennsylvania alumna, Karin Eisinger, PhD | CEO, + University of North Carolina at Chapel Hill alumna, Ashley M. Fuller, PhD, PhD, | CSO SyzOnc aims to develop therapies for cancer patients who have no effective treatment options. Grounded in world-class oncology and machine learning research from Penn and the Broad Institute, they are targeting matrix-rich solid tumors by tackling multi-faceted protein targets. + 𝗟𝗼𝗰𝗮𝘁𝗶𝗼𝗻: United States + 𝗙𝗼𝘂𝗻𝗱𝗲𝗱: 2023 + 𝗧𝗲𝗮𝗺 𝗦𝗶𝘇𝗲: 3 + 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆: Biotechnology, Pharmaceuticals, Artificial Intelligence (AI), Life Sciences Read the interview with Anne Carpenter: https://lnkd.in/gpnZWfN8 #crimsonfounders #TheFounderFiles #mitalumni #HarvardAlumni #mitsloan #startups #MITStartups #healthcare #biotech #pharmaceuticals #ai #artificialintelligence

We are very excited to announce Dr Hanadie Yousef will be a speaker for the VoT entrepreneurship track! Hanadie is the CEO and co-founder of Juvena Therapeutics https://lnkd.in/dD7-w_En, an AI-enabled biopharma unlocking the therapeutic potential of secreted proteins to develop biologics for chronic muscle and metabolic diseases. The company will be entering the clinic with its lead candidate, a muscle regenerating biologic being developed first for Myotonic Dystrophy Type 1 later this year. In addition, Juvena is progressing multiple preclinical programs, including a novel obesity asset with a unique, non-appetite suppressing mechanism. Hanadie’s scientific background focused on the biology of aging and mechanisms underlying tissue degeneration and her biomedical research, with support from the NIH, NSF, CIRM, and others has led to multiple issued and pending patents and high-impact first authorships. As a first-time founder, she is honored to be among the 2023 “Fiercest Women in Life Sciences,” Business Insider’s “30 Leaders Under 40 Changing Healthcare in 2023,” and Endpoints “The 20(+2) under 40.” She earned her PhD from UC Berkeley as an NSF graduate research fellow then completed a 5-year postdoc at Stanford School of Medicine as an NIH fellow and SPARK scholar. Only 4 days left to apply for the opportunity to meet our speakers: https://lnkd.in/dTGuA6hi #biotech #entrepreneurship #competition

I read at the beginning of the year the trends for biotech in 2024. The biotech industry’s landscape is vibrant and brimming with potential, driven by innovation and fostering space for startups. The resurgence of M&A activities, AI's impact, and advances in RNA technology, CRISPR, bioprinting, tissue engineering, stem cell research, and targeted protein degradation signify significant progress in our industry. Challenges ahead include navigating complex regulatory environments, addressing ethical considerations, and ensuring sustainable and equitable access to groundbreaking technologies. Collaborations between smaller biotech's and pharmaceutical giants, ethical AI deployment, and responsible CRISPR application all demand a balanced approach considering long-term implications. What do you think will be the main focus for Biotechnology in 2025? Have you noticed other emerging trends in the industry? I'm keen to understand from you what you think is the future of biotech! #biotechnology #trends2025 #kaizenlifesciences #startups

Last April at the Bloom Burton & Co. conference in Toronto, Nancy Harrison and Ali Tehrani of Amplitude Ventures pulled me aside for what they said was an important conversation. There’s something special going on in Vancouver's life sciences sector and you need to write about it, they said. I had already noted many of Canada’s most prominent life sciences companies – like AbCellera, Xenon Pharmaceuticals Inc. , STEMCELL Technologies, Acuitas Therapeutics and Aspect Biosystems – were all based in Canada’s west coast capital and wondered what was behind that. I told them I was interested to know more, and they helped put me in touch with a slew of people representing a cross-section of the local sector. That November I came to Vancouver and spent four marathon days meeting with founders, funders, academics, industry and government representatives and administrators including Wendy Hurlburt, Lana Janes, Ph.D., Carl Hansen, Pieter Cullis, Dermot Kelleher Tom Madden, Ali Ardakani Bill Hunter, Megan Levings, Jerel Davis, Peter Zandstra, Natalie Dakers, Fiona Dalton, Sriram Subramaniam and others. I interviewed about 50 people in total including BC innovation minister Brenda Bailey I also saw some cool science too, including tiny brain “organoids” grown in petri dishes at Stemcell, a giant electron microscope at the service of Dr. Subramaniam on the The University of British Columbia campus, a production facility at Clarius Mobile Health that manufactured handheld, wireless ultrasound readers and a 3D printing machine at Aspect that made synthetic, transplantable tissue. I concluded that Nancy and Ali were right. Sharing with you here the cover story that came out of this. It's about what has made Vancouver this country's most exciting and advanced biotech capital, and how leading players are determined to transform the city – and by turn Canada – into a haven for homegrown pharma giants. It’s about time; we’ve never had one. Canadians discovered insulin a century ago and we’ve made many breakthrough discoveries since, but that science ultimately gets commercialized elsewhere, creating major economic spinoff benefits outside Canada. At a time when Canada's woeful productivity performance is under heightened scrutiny, it’s noteworthy to see an innovative local sector’s players working with such determination and unity. If they succeed – and there is a long way to go – in putting together the missing pieces for a full-stack ecosystem, perhaps they can build a thriving, vertically integrated industry that would bring jobs & prosperity to the region. They are following a roadmap that should serve as a guide to others across Canada. But it’s early days. And Vancouver has been here before; things didn't end well the 1st time. Gordon McCauley (He/Him) adMare BioInnovations, Abdera Therapeutics Francois Benard Angus Livingstone BC Children's Hospital, Vancouver Martha Piper Karimah Es Sabar Andrew Booth Chrystia Freeland François-Philippe Champagne

Emerging Therapeutic Innovation Models: In last 2 years, venture and philanthropy deploy $4.5B across three companies for basic and translational research. One model claims to bypass limitations of NIH funding and academic institutions. High-level notes from press releases. Interested in your thoughts. 1. Funding: Arena $500M. Altos $3B. Xiara $1B 2. Focus: (a) Arena - determining the mechanisms of human disease and advancing new technologies to translate these insights into therapeutics through in-house biotech companies (b) Altos - restore cell health and resilience to reverse disease, injury, and the disabilities that can occur throughout life. (c) Xiara - AI Enabled Drug Discovery for traditionally undruggable targets. 3. Press Releases Arena - https://lnkd.in/e4hksYnD Altos - https://lnkd.in/etc-Ax44 Xiara - https://lnkd.in/e3-AiJjT

Today, San Diego, is the fastest-growing biotech hub in the US❗ But how exactly did San Diego become the go-to destination for biotechnology? San Diego’s biotech story began back in 1955-1965 when leading research institutions such as the Salk Institute, Scripps, and the University of California San Diego (UCSD) were founded close to one another. City leaders designated Torrey Pines to scientific research and development. In 1978, two young UC San Diego academics named Ivor Royston and Howard Birndorf had an idea. He believed his research into monoclonal antibodies could be the future of disease diagnosis. He and his assistant, Howard Birndorf, hoped to begin making the antibodies commercially for hepatitis testing. Using the new science of biotechnology, they could make better products for research and therapy. Their idea became Hybritech, San Diego’s first biotech company. By the early 80s, San Diego attracted complementary firms, patent attorneys, venture capitalists and PR companies, all eager to support innovative start-ups, creating medical breakthroughs. Hybritech was sold for $450 million in 1986. Today, a quarter of San Diego’s Life Sciences organizations have roots that can be traced back to Hybritech, reports Biocom. So, I think it’s safe to say there wouldn’t be such a successful biotech business in San Diego without researchers like Royston, who himself went on to become a venture capitalist to invest in local Life Sciences. In the early 90s, as the Cold War was winding down, defense spending in the area had decreased, meaning San Diego-based aerospace companies were closing their doors. The local economy collapsed, and California faced its gravest recession in over 50 years. To secure more biotech business, civic leaders agreed to relax some of the city’s rigid regulations surrounding construction, permits, and zoning. Because of the loosening of rules, along with the research from UCSD, the Salk Institute, the Burnham Institute, and Scripps, a tidal wave of biotech businesses emerged. In 1995, Biocom was formed to be the voice of the Life Sciences industry in California. Today, San Diego’s Life Sciences industry is thriving, from Biotech, Pharmaceutical, Healthcare and Medical Devices. While San Diego has a rich history that has planted its feet firmly in the sand of Life Sciences, start-ups continue to emerge and grow, expanding economic value, attracting skilled workers, and contributing to the INNOVATION Ecosystem. INNOVATE SAN DIEGO will feature the people, products, services, technologies and contributors who make this possible. Please use the link below to submit a thought leader or company who you believe should be showcased as a Life Sciences contributor in the upcoming book, INNOVATE SAN DIEGO. https://lnkd.in/g_ikdGWm #BiotechSD #MedicalDeviceSD #PharmaceuticalSD